Thursday 16 October, 2025
Objectives: Automated population pharmacokinetic modelling tools are currently being investigated. The genetic algorithm (GA) has been proposed to address pharmacometric…
Read moreAbstracts
Development and evaluation of nlmixr2auto: Automated open-source model building
Thursday 16 October, 2025
Introduction/Objectives. Complex pharmacometric model building reduces the time available to focus on interpretation and application of results. Automated modelling leverages…
Read moreA translational minimal physiologically-based pharmacokinetic (mPBPK) model to predict preclinical and clinical PK of MEN1703 in tissues
Thursday 16 October, 2025
Objectives: MEN1703 is a novel dual kinase inhibitor targeting PIM and FLT3 kinases, currently under investigation in patients with acute…
Read moreModeling spatial pharmacokinetics of drugs in mucus in patients with cystic fibrosis
Thursday 16 October, 2025
Introduction: Cystic fibrosis (CF) is a genetic disease causing extensive mucus formation in lung[1], and which is associated with chronic…
Read morePopulation pharmacokinetics of continuous infusion ampicillin in the treatment of enterococcal infections in adult hospitalised patients
Thursday 16 October, 2025
Acknowledgement: This project has received funding from European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant…
Read morePopulation Pharmacokinetics of cabozantinib in adult metastatic renal cell carcinoma patients: evaluation of real-world data
Thursday 16 October, 2025
Introduction: Cabozantinib, a second-generation receptor tyrosine kinase inhibitor, is approved for the treatment of metastatic renal cell carcinoma (mRCC) at a…
Read morePopulation pharmacokinetic analysis of pazopanib in adult patients with metastatic renal cell carcinoma and soft tissue sarcoma
Thursday 16 October, 2025
Introduction: Pazopanib is a multi-target receptor tyrosine kinase inhibitor (TKI), and part of the current standard of care of metastatic…
Read moreModel-informed pazopanib dose optimization in real-world cancer patients
Thursday 16 October, 2025
Introduction: Pazopanib is currently used for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) at an…
Read moreModel-derived PK target profile of ustekinumab therapeutic thresholds in inflammatory bowel diseases to guide precision dosing
Thursday 16 October, 2025
Objectives: Inflammatory bowel diseases (IBD) are a group of chronic immune-mediated diseases affecting the gastrointestinal tract, causing debilitating symptoms such…
Read moreA pharmacometric evaluation of atypical plasma protein binding and probability of target attainment of tigecycline in obese and nonobese patients
Thursday 16 October, 2025
Objectives: Tigecycline is a broad-spectrum antibiotic [1] used to treat complicated intraabdominal infections (cIAI), community acquired pneumonia (CAP) and complicated…
Read more